Simple Summary There are currently no blood biomarkers approved for routine clinical use
in endometrial cancer. Serum human epididymis protein 4 (HE4) is significantly higher in …

Introduction: Endometrial cancer is the most common gynaecological cancer and its
incidence is rising due to increasing obesity rates. We are also seeing an increasing trend of …

Despite the improvement in overall survival for ovarian cancer (OC) patients, a fraction of
patients with advanced-stage disease fails to respond to primary therapy and relapses in …

Introduction Endometrial cancer, one of the most frequent pelvic gynecologic cancer
worldwide, currently has no biomarker used to assess it in daily practice. Nonetheless …

Objective: To date, biomarkers are not routinely used in endometrial cancer diagnosis,
prognosis, and follow-up. The purpose of this study was to evaluate whether serum HE4 was …

There is no recognized serum biomarker to predict the recurrence of endometrial carcinoma
(EC). We aimed to explore serum human epididymis protein 4 (HE4) and cancer antigen …

Human epididymis protein 4 (HE4) is an important clinical biomarker used for the detection
of epithelial ovarian cancer (EOC). While much is known about the predictive power of HE4 …

Simple Summary Although the field of liquid biopsy is clearly having an effect on other
tumour types, in endometrial cancer (EC) there is important work to do to implement the …

Objectives To investigate whether HE4 and CA125 could identify endometrioid
adenocarcinoma patients who might most benefit from full staging surgery with …

Background There is no consensus on the correlation between human epididymis protein 4
(HE4) and prognosis of endometrial cancer (EC). Therefore, we performed a meta‐analysis …